Company Overview

PRIME exits® and American Healthcare Capital are pleased to offer an opportunity to acquire an integrated speech therapy technology and clinical services platform located in Northern California. Founded over a decade ago, the company combines a technology division that has developed proprietary, AI-driven tools for speech-language assessment and autism intervention—supported by more than $2.28M in non-dilutive federal and corporate grants—and a clinical services division providing NPA-certified speech-language pathology services to a major health system, regional centers, and multiple school districts. The company also owns and publishes a specialized autism-focused magazine with 15+ years of brand equity. All technology products are built on HIPAA/FERPA-compliant architecture.

Key Highlights

• Dual-revenue engine: Contract-based clinical revenue paired with scalable AI and digital products in the $8B+ special education technology market.

• Validated AI platform: Flagship speech evaluation technology reduces assessment time from 6 hours to 15 minutes with 98–99% accuracy, de-risked and funded by competitive federal grants. Clinicians bill $65–$500 per assessment while reducing delivery time by 95%.

• Proprietary clinical dataset: 9,000–10,000+ de-identified HIPAA-compliant clinical files accumulated over 13 years—an irreplaceable competitive moat with active LLM integration for AI training. Standalone valuation: $2.5M–$5M.

• Distribution partnership launching Q1 2026: Commercial launch of AI platforms through a major industry partner, providing immediate access to 150,000+ global SLP and school-district customers.

• Strong clinical recovery: 366 active clients as of early 2026, with active hiring and expansion plans targeting 5–10 new clients per week.

• Dramatic cost restructuring: 75%+ reduction in R&D costs via in-house development shift, driving significant margin expansion.

• Medical credentialing in progress: Applications submitted to 9 major insurance networks—buyer inherits head start on payer diversification.

• Experienced leadership: Founder team with deep clinical + AI expertise committed to 12–24-month transition support.

Financial Overview

The combined operations have a 13-year track record of revenue generation and profitability. Revenue grew from $887,010 in 2022 to $1,001,530 in 2023 and totaled $924,000 in 2024 with normalized EBITDA of $406,000–$476,000 (44–52% margin).2025 revenue was $591,000, reflecting a temporary contraction from Kaiser Permanente client attrition and two staff departures. The reported net loss of ($62,884) is entirely attributable to $255,000 in discretionary R&D investment in AI platform development. Excluding this investment, the clinical operations generated approximately $202,000 in EBITDA—a 34% margin.Heading into 2026, the business has recovered to 366 active clients, R&D costs have been reduced by 75%+ through in-house development, and a major distribution partnership is launching. Projected 2026 revenue is $847,000–$1.45 million with significantly improved margins.Expected to close debt-free, with approximately $286,000 of existing debt retired by the sellers or immediately after closing.

Opportunity

• Scaling the AI evaluation and IEP compliance tools via existing and new distribution channels (150,000+ SLP reach).

• Expanding clinical services into additional school districts, insurance networks (9 applications in process), and geographic markets.

• Leveraging the proprietary clinical dataset for next-generation AI product development.

• Capturing $540,000–$648,000 in immediate NPA expansion revenue from 40% unused capacity.

• Scaling per-assessment model into school districts and clinics where SLP burnout creates immediate demand.

Transaction

The owners are exploring a sale of 100% of the ownership in both the technology and clinical entities. The clinical services component will be valued on a multiple of EBITDA, and the technology/IP portfolio will be valued based on development investment, proprietary dataset replacement cost, and commercialization potential. Consideration will include a cash component at closing plus a performance-based earnout and potential royalties tied to technology revenue. Sellers will commit to 12–24-month transition support.